Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET microdosing study of sorafenib and erlotinib tumor concentrations in advanced solid tumors
2012-004961-42Phase 2Active
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib and erlotinib in Non-hematologic malignancy (2 cohorts), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Tumor detection of radiolabeled kinase inhibitor. Started Feb 2013; status: active.
02
Drugs
sorafeniberlotinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2012-004961-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004961-42.